Evidence map›Paper›PMID 35027443›Full record

ArticleJournal of psychiatry & neuroscience : JPN

Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels.

Ryo Ochi, Eric Plitman, Raihaan Patel, Ryosuke Tarumi, Yusuke Iwata, Sakiko Tsugawa, Julia Kim, Shiori Honda, Yoshihiro Noda, Hiroyuki Uchida and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. The role of affective states in computational psychiatry.The international journal of neuropsychopharmacology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Scalable NMF via linearly optimized data compression.Proceedings of SPIE--the International Society for Optical Engineering · 2023
    Article
  15. Scalable Orthonormal Projective NMF via Diversified Stochastic Optimization.Information processing in medical imaging : proceedings of the ... conference · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Ryo OchiFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Eric PlitmanFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Raihaan PatelFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Ryosuke TarumiFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Yusuke IwataFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Sakiko TsugawaFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Julia KimFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Shiori HondaFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Yoshihiro NodaFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Hiroyuki UchidaFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Gabriel A DevenyiFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Masaru MimuraFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Ariel Graff-GuerreroFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
M Mallar ChakravartyFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero).
Shinichiro NakajimaFrom the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Ochi, Tarumi, Tsugawa, Honda, Noda, Uchida, Mimura, Nakajima); the Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Que., Canada (Plitman, Patel, Devenyi, Chakravarty); the Department of Psychiatry, McGill University, Montreal, Que., Canada (Plitman, Devenyi, Chakravarty); the Department of Biological and Biomedical Engineering, McGill University, Montreal, Que., Canada (Patel, Chakravarty); the Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ont., Canada (Iwata, Kim, Graff-Guerrero, Nakajima); and the Institute of Medical Science, University of Toronto, Toronto, Ont., Canada (Kim, Graff-Guerrero) shinichiro_nakajima@hotmail.com.
Keio University · JPCentre for Addiction and Mental Health · CAMcGill University · CAUniversity of Toronto · CAHonda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbnormalities in the anterior cingulate cortex (ACC) are thought to play an important role in the pathophysiology of schizophrenia. Given regional variations in ACC structure, the present study aimed to examine ACC structural subdivisions and their relationships to treatment resistance and glutamatergic levels in schizophrenia.

methodsThis study included 100 patients with schizophrenia and 52 healthy controls from 2 cohorts. We applied non-negative matrix factorization to identify accurate and stable spatial components of ACC structure. Between groups, we compared ACC structural indices in each spatial component based on treatment resistance or response and tested relationships with ACC glutamate + glutamine levels.

resultsWe detected reductions in cortical thickness and increases in mean diffusivity in the spatial components on the surface of the cingulate sulcus, especially in patients with treatment-resistant and clozapine-resistant schizophrenia. Notably, mean diffusivity in these components was higher in patients who did not respond to clozapine compared to those who did. Furthermore, these ACC structural alterations were related to elevated ACC glutamate + glutamine levels but not related to symptomatology or antipsychotic dose. LIMITATIONS: Sample sizes, cross-sectional findings and mixed antipsychotic status were limitations of this study.

conclusionThis study identified reproducible abnormalities in ACC structures in patients with treatment-resistant and clozapine-resistant schizophrenia. Given that these spatial components play a role in inhibitory control, the present study strengthens the notion that glutamate-related disinhibition is a common biological feature of treatment resistance in schizophrenia.

Indexed as

Antipsychotic AgentsClozapineSchizophreniaCross-Sectional StudiesGlutamic AcidGlutamineGyrus CinguliHumansAntipsychotic AgentsClozapineGlutamic AcidGlutamine

Identifiers

PMID35027443
PMCPMC8842685
OpenAlexW4205241944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.